NervGen Pharma (NASDAQ:NGEN) Issues Earnings Results

NervGen Pharma (NASDAQ:NGEN) released its quarterly earnings results on Friday. The company reported $999.00 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $999.07, reports.

NervGen Pharma Price Performance

Shares of NASDAQ:NGEN opened at $3.57 on Friday. NervGen Pharma has a 1 year low of $1.50 and a 1 year high of $6.30.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on NGEN shares. Stifel Nicolaus upgraded NervGen Pharma to a “strong-buy” rating in a research report on Thursday, April 23rd. HC Wainwright upgraded NervGen Pharma to a “strong-buy” rating in a research report on Tuesday, April 28th. Weiss Ratings assumed coverage on NervGen Pharma in a research note on Friday, April 24th. They set a “sell (d-)” rating on the stock. Zacks Research raised NervGen Pharma to a “hold” rating in a research note on Wednesday, April 29th. Finally, Wall Street Zen cut NervGen Pharma from a “sell” rating to a “strong sell” rating in a research note on Wednesday. Two analysts have rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, NervGen Pharma has an average rating of “Moderate Buy” and a consensus price target of $18.00.

NervGen Pharma Company Profile

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.